Jacobs & Co. CA Has $13.63 Million Position in Eli Lilly and Company (NYSE:LLY)

Jacobs & Co. CA lessened its position in Eli Lilly and Company (NYSE:LLY) by 5.1% in the fourth quarter, Holdings Channel.com reports. The firm owned 23,388 shares of the company’s stock after selling 1,263 shares during the quarter. Eli Lilly and Company comprises 1.5% of Jacobs & Co. CA’s portfolio, making the stock its 18th biggest holding. Jacobs & Co. CA’s holdings in Eli Lilly and Company were worth $13,633,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Fairfield Bush & CO. acquired a new stake in shares of Eli Lilly and Company in the first quarter valued at about $107,000. Roundview Capital LLC grew its stake in Eli Lilly and Company by 2.6% during the first quarter. Roundview Capital LLC now owns 2,056 shares of the company’s stock worth $589,000 after purchasing an additional 53 shares during the period. Merit Financial Group LLC acquired a new stake in Eli Lilly and Company during the first quarter worth approximately $210,000. NewEdge Advisors LLC grew its stake in Eli Lilly and Company by 9.9% during the first quarter. NewEdge Advisors LLC now owns 53,052 shares of the company’s stock worth $15,193,000 after purchasing an additional 4,774 shares during the period. Finally, Barometer Capital Management Inc. acquired a new stake in Eli Lilly and Company during the first quarter worth approximately $561,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

NYSE LLY opened at $778.69 on Thursday. The business’s fifty day moving average price is $727.96 and its 200-day moving average price is $636.01. The stock has a market capitalization of $739.88 billion, a price-to-earnings ratio of 134.26, a PEG ratio of 1.70 and a beta of 0.34. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. Eli Lilly and Company has a 1-year low of $334.58 and a 1-year high of $800.78.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping the consensus estimate of $2.30 by $0.19. The firm had revenue of $9.35 billion during the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. Eli Lilly and Company’s revenue was up 28.1% on a year-over-year basis. During the same period in the prior year, the business posted $2.09 EPS. On average, equities analysts predict that Eli Lilly and Company will post 12.42 earnings per share for the current year.

Insiders Place Their Bets

In other news, major shareholder Lilly Endowment Inc sold 34,538 shares of the firm’s stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $631.81, for a total transaction of $21,821,453.78. Following the completion of the transaction, the insider now owns 99,719,884 shares in the company, valued at $63,004,019,910.04. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In the last quarter, insiders sold 195,055 shares of company stock worth $125,254,657. Corporate insiders own 0.13% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. JPMorgan Chase & Co. increased their price target on Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a report on Friday, March 15th. DZ Bank lowered Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price on the stock. in a report on Wednesday, February 21st. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Barclays raised their target price on Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a report on Wednesday, February 7th. Finally, Morgan Stanley raised their target price on Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a report on Friday, February 16th. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average target price of $689.52.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.